Updated from 2:27 p.m. EDT
were among health and pharmaceutical losers Thursday, falling 4.7% after the company announced the sale of 6.5 million shares at $6.10 apiece.
Proceeds of about $40 million will be used to help fund the company's cancer trials. With this financing, Geron's cash position now stands at about $130 million. The sale price represents a 16% discount to Wednesday's closing price. Shares of the biopharmaceutical company traded down 34 cents to $6.96.
rose 3.1% after the company posted a third-quarter loss. The neuroscience company posted an operating loss of $1.4 million vs. a year-ago loss of $1.5 million.
The company also provided updated guidance on its drug for Huntington's disease. The drug, which has been granted fast-track status, is due to start another phase III trial during the first half of 2005. The company is in the process of finalizing the clinical trial protocol using information gleaned from its first phase III trial, other analyses, and suggestions from the U.S. Food and Drug Administration and the European Medicines Evaluation Agency. Shares of Amarin traded up 9 cents to $3.
( ZOLL) fell 5.1% after the company's fourth-quarter earnings fell short of Wall Street expectations. The maker of resuscitation devices earned 23 cents a share on sales of $55.7 million. The earnings were in line with the company's previous guidance but fell 2 cents short of analysts' expectations. The company called its international results "disappointing" and said it has made several management changes to address the situation. Shares traded down $1.70 to $31.35.
Other health care volume movers included
, down 32 cents to $27.15;
, down 26 cents to $26.15;
Teva Pharmaceutical Industries
, up $1.34 to $27.32;
, down 52 cents to $38.62;
Johnson & Johnson
, up 48 cents to $60.60;
( SGP), up 21 cents to $18.62; and
, up 54 cents to $59.88.